BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morbach C, Marx A, Kaspar M, Güder G, Brenner S, Feldmann C, Störk S, Vollert JO, Ertl G, Angermann CE; INH Study Group and the Competence Network Heart Failure. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides. Eur J Heart Fail 2017;19:1166-75. [PMID: 28516504 DOI: 10.1002/ejhf.859] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Stătescu C, Anghel L, Tudurachi B, Leonte A, Benchea L, Sascău R. From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction. IJMS 2022;23:9168. [DOI: 10.3390/ijms23169168] [Reference Citation Analysis]
2 Simonavičius J, Mikalauskas A, Čerlinskaitė K, Gayat E, Juknevičius V, Palevičiūtė E, Alitoit-Marrote I, Kablučko D, Bagdonaitė L, Balčiūnas M, Vaičiulienė D, Jonauskienė I, Motiejūnaitė J, Stašaitis K, Kukulskis A, Damalakas Š, Šimbelytė T, Taparauskaitė N, Pukanasienė G, Laucevičius A, Kavoliūnienė A, Mebazaa A, Čelutkienė J; GREAT network. Biologically Active Adrenomedullin (bio-ADM) is of potential value in identifying congestion and selecting patients for neurohormonal blockade in acute dyspnea. Am J Med 2022:S0002-9343(22)00133-4. [PMID: 35245495 DOI: 10.1016/j.amjmed.2022.02.006] [Reference Citation Analysis]
3 Kita T, Kitamura K. Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases. Hypertens Res 2022. [PMID: 34992239 DOI: 10.1038/s41440-021-00806-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Aleksova A, Sinagra G, Beltrami AP, Pierri A, Ferro F, Janjusevic M, Gagno G. Biomarkers in the management of acute heart failure: state of the art and role in COVID-19 era. ESC Heart Fail 2021. [PMID: 34609075 DOI: 10.1002/ehf2.13595] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Lombardi CM, Cimino G, Pellicori P, Bonelli A, Inciardi RM, Pagnesi M, Tomasoni D, Ravera A, Adamo M, Carubelli V, Metra M. Congestion in Patients with Advanced Heart Failure: Assessment and Treatment. Heart Fail Clin 2021;17:575-86. [PMID: 34511206 DOI: 10.1016/j.hfc.2021.05.003] [Reference Citation Analysis]
6 Kozhuharov N, Ng L, Wussler D, Strebel I, Sabti Z, Hartmann O, Eltayeb M, Squire I, Nowak A, Rieger M, Martin J, Michou E, Stefanelli S, Puelacher C, Shrestha S, Belkin M, Zimmermann T, Lopez-Ayala P, Struck J, Bergmann A, Mebazaa A, Blet A, Gualandro DM, Breidthardt T, Mueller C. Activity of the adrenomedullin system to personalise post-discharge diuretic treatment in acute heart failure. Clin Res Cardiol 2021. [PMID: 34302189 DOI: 10.1007/s00392-021-01909-9] [Reference Citation Analysis]
7 García de Guadiana-Romualdo L, Calvo Nieves MD, Rodríguez Mulero MD, Calcerrada Alises I, Hernández Olivo M, Trapiello Fernández W, González Morales M, Bolado Jiménez C, Albaladejo-Otón MD, Fernández Ovalle H, Conesa Hernández A, Azpeleta Manrique E, Consuegra-Sánchez L, Nogales Martín L, Conesa Zamora P, Andaluz-Ojeda D. MR-proADM as marker of endotheliitis predicts COVID-19 severity. Eur J Clin Invest 2021;51:e13511. [PMID: 33569769 DOI: 10.1111/eci.13511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Czajkowska K, Zbroch E, Bielach-Bazyluk A, Mitrosz K, Bujno E, Kakareko K, Rydzewska-Rosolowska A, Hryszko T. Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases-Is It the Future? J Clin Med 2021;10:524. [PMID: 33540505 DOI: 10.3390/jcm10030524] [Reference Citation Analysis]
9 Palazzuoli A, Evangelista I, Nuti R. Congestion occurrence and evaluation in acute heart failure scenario: time to reconsider different pathways of volume overload. Heart Fail Rev 2020;25:119-31. [PMID: 31628648 DOI: 10.1007/s10741-019-09868-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
10 Hashemi D, Blum M, Mende M, Störk S, Angermann CE, Pankuweit S, Tahirovic E, Wachter R, Pieske B, Edelmann F, Düngen HD; German Competence Network for Heart Failure. Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany. ESC Heart Fail 2020;7:942-52. [PMID: 32003157 DOI: 10.1002/ehf2.12605] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Rosano GMC, Seferović PM. Physiological monitoring in the complex multi-morbid heart failure patient - Introduction. Eur Heart J Suppl 2019;21:M1-4. [PMID: 31908606 DOI: 10.1093/eurheartj/suz229] [Reference Citation Analysis]
12 Kuan WS, Ibrahim I, Chan SP, Li Z, Liew OW, Frampton C, Troughton R, Pemberton CJ, Chong JPC, Tan LL, Lin W, Ooi SBS, Richards AM. Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation. Eur J Heart Fail 2020;22:692-700. [PMID: 31808279 DOI: 10.1002/ejhf.1660] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Trincot CE, Xu W, Zhang H, Kulikauskas MR, Caranasos TG, Jensen BC, Sabine A, Petrova TV, Caron KM. Adrenomedullin Induces Cardiac Lymphangiogenesis After Myocardial Infarction and Regulates Cardiac Edema Via Connexin 43. Circ Res 2019;124:101-13. [PMID: 30582443 DOI: 10.1161/CIRCRESAHA.118.313835] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
14 Darden D, Nishimura M, Sharim J, Maisel A. An update on the use and discovery of prognostic biomarkers in acute decompensated heart failure. Expert Rev Mol Diagn 2019;19:1019-29. [PMID: 31539485 DOI: 10.1080/14737159.2019.1671188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
15 Möckel M, Koehler K, Anker SD, Vollert J, Moeller V, Koehler M, Gehrig S, Wiemer JC, Haehling S, Koehler F. Biomarker guidance allows a more personalized allocation of patients for remote patient management in heart failure: results from the TIM‐HF2 trial. Eur J Heart Fail 2019;21:1445-58. [DOI: 10.1002/ejhf.1530] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
16 Spinar J, Spinarova L, Malek F, Ludka O, Krejci J, Ostadal P, Vondrakova D, Labr K, Spinarova M, Pavkova Goldbergova M, Benesova K, Jarkovsky J, Parenica J. Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry. PLoS One 2019;14:e0214363. [PMID: 30913251 DOI: 10.1371/journal.pone.0214363] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
17 Correale M, Monaco I, Brunetti ND, Di Biase M, Metra M, Nodari S, Butler J, Gheorghiade M; Master Program Students on Drug Development for Heart Failure. Redefining biomarkers in heart failure. Heart Fail Rev 2018;23:237-53. [PMID: 29511896 DOI: 10.1007/s10741-018-9683-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
18 Tsuruda T, Kato J, Kuwasako K, Kitamura K. Adrenomedullin: Continuing to explore cardioprotection. Peptides 2019;111:47-54. [DOI: 10.1016/j.peptides.2018.03.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
19 Grieco P, Gomez-Monterrey I. Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials. Arch Biochem Biophys 2019;662:15-32. [PMID: 30481494 DOI: 10.1016/j.abb.2018.11.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
20 Hollinger A, Cerlinskaite K, Bastian K, Mebazaa A. Biomarkers of increased intraventricular pressure: are we ready? European Heart Journal Supplements 2018;20:G21-7. [DOI: 10.1093/eurheartj/suy025] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Crespo-leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, Gustafsson F, Tsui S, Barge-caballero E, De Jonge N, Frigerio M, Hamdan R, Hasin T, Hülsmann M, Nalbantgil S, Potena L, Bauersachs J, Gkouziouta A, Ruhparwar A, Ristic AD, Straburzynska-migaj E, Mcdonagh T, Seferovic P, Ruschitzka F. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology: Advanced heart failure: HFA position statement. Eur J Heart Fail 2018;20:1505-35. [DOI: 10.1002/ejhf.1236] [Cited by in Crossref: 217] [Cited by in F6Publishing: 263] [Article Influence: 54.3] [Reference Citation Analysis]
22 Mueller C. Clinical utility of biomarkers in heart failure. Eur J Heart Fail 2017;19:1176-8. [PMID: 28580774 DOI: 10.1002/ejhf.893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]